Valneva SE (VALN) fair value analysis
Nasdaq · Updated 2026-09-12
Valneva SE is a biopharmaceutical company that develops and commercializes vaccines for infectious diseases. The company operates in Europe and has a presence in multiple countries including France and Austria.
Valuation status
Awaiting full valuationVALN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $6.57
- Sector
- Healthcare
- 12-month range
- $5.07–$11.57
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- F
- Leverage
- High
- Margin trend
- Contracting
- Revenue growth
- Declining
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The bottom quarter of its range
What our data shows for VALN
- Shares are trading in the lower third of their 12-month price range of $5.07–$11.57.
- The 14-day relative strength index sits at a neutral 62.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for VALN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent VALN news
TickrTrends' derived news-sentiment signal for VALN is currently leaning positive, computed from recent coverage.
- Big Pharma Stocks Rebound After Germany’s Merkel Speaks Out Against Vaccine Patent Waiver – Jake Johnson (05 (wallstreetwindow.com, 2021-05-12)
- Valneva Announces Closing Of $107.6 Million Global Offering (thestreet.com, 2021-05-11)
- Valneva Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $107.6 Million (markets.businessinsider.com, 2021-05-10)
What people are saying
Follow the VALN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-12 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is VALN stock undervalued?
VALN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is VALN's TickrTrends verdict?
VALN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is VALN overbought or oversold?
VALN's 14-day RSI is in neutral territory - neither overbought nor oversold.